
Celcuity (CELC) Stock Forecast & Price Target
Celcuity (CELC) Analyst Ratings
Bulls say
Celcuity is expected to continue its strong performance with the potential approval and commercialization of gedatolisib in advanced breast cancer, with increased market share and sales estimates. Additionally, the company's ongoing and planned operations show a strong level of preparedness and potential for international expansion. An enhanced financial model and increased probability of success for the PIK3CAmt cohort has resulted in a higher price target for the company's stock.
Bears say
Celcuity is currently facing a negative outlook due to the potential for limited efficacy of their candidate gedatolisib compared to already established treatments such as Roche's INAVO120, high operating expenses, and a potentially limited patient population for their VIKTORIA-2 trial. Despite recent data validating the importance of PIK3CA mutations, which could potentially expand eligibility in future trials, the company's current financials and the focus on dosing patients in the safety lead-inportion of the trial suggest a longer timeline for profitability.
This aggregate rating is based on analysts' research of Celcuity and is not a guaranteed prediction by Public.com or investment advice.
Celcuity (CELC) Analyst Forecast & Price Prediction
Start investing in Celcuity (CELC)
Order type
Buy in
Order amount
Est. shares
0 shares